Trade Longeveron Inc. - LGVN CFD

Longeveron Inc. (LGVN) is a clinical-stage biotechnology company. Its lead drug component and cellular therapies address ageing and other life-threatening conditions. Founded in 2014, Longeveron is headquartered in Miami, US. 

The biotech firm’s leading product Lomecel-B is derived from culture-expanded medicinal signalling cells (MSCs). The cells were sourced from young healthy adult donors’ - aged 18 to 45 - bone marrow to treat ageing-related diseases as they promote cell and tissue repair, organ maintenance and immune system function.

As of June 2022, the company is conducting Phase 2 clinical trials in hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease. It has received orphan drug and rare paediatric disease designations from the US Food and Drug Administration (FDA). 

Longeveron is also conducting Phase 1 and 2 clinical trials for ageing frailty, metabolic syndrome and acute respiratory distress syndrome due to Covid-19 or influenza.

Longeveron’s programmes have been awarded grant funding of more than $16.2m from various organisations, including the National Institute on Ageing (NIA), National Heart Lung and Blood Institute (NHLBI), the Alzheimer’s Association and the Maryland Stem Cell Research Fund (MSCRF).

Longeveron Inc. stock started trading on the NASDAQ stock exchange in February 2021 under the ticker symbol LGVN. 

You can follow live LGVN stock price movements and price history and keep up with the latest LGVN share value at Capital.com